 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Guilford Pharmaceuticals Inc.
 |
Guilford Pharmaceuticals Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Guilford falls on jitters about Parkinson's drug Jul 26 2001 10:35 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Brain rot be gone! Guilford Pharmaceuticals develops therapeutic and diagnostic products to treat neurological diseases, as well as drug-delivery systems for treating cancer. The firm's first approved delivery system, GLIADEL, is a medicinal wafer placed in the space left when a brain tumor is removed. The company is working with Amgen to develop NIL-A and other orally administered drugs that regenerate nerve cells in patients with Parkinson's disease, spinal injuries, Alzheimer's, and other disorders. DOPASCAN, an intravenous solution to diagnose and monitor Parkinson's disease, is also in development.
COMPETITION |
 |
Advanced Neuromodulation Systems, Inc. (ANSI)
Cephalon, Inc. (CEPH)
NeoTherapeutics, Inc. (NEOT)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 18.10
1-Yr. Sales Growth: (16.2)%
Employees: 254
Revenue per employee: $71,259.84
KEY PEOPLE |
 |
Craig R. Smith
CEO
Andrew R. Jordan
CFO
CONTACT INFO |
 |
6611 Tributary St.
Baltimore, MD 21224
US
Phone: 410-631-6300
Fax: 410-631-6338
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |